Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ODSH · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ODSH | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ODSH | DRUG | - |
Inclusion Criteria: * Newly diagnosed, previously untreated acute myeloid leukemia. Acute promyelocytic leukemia is excluded. * No prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to control white blood cell count is allowed. * No prior chemotherapy or lenalinomide for trea...
ODSH is an investigational small molecule being studied for use in Acute Myeloid Leukemia (AML). It was evaluated in a Phase 1 clinical trial in patients receiving induction or consolidation therapy for AML. The drug is still in clinical development and is not approved by the FDA.
ODSH is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company traded on the NASDAQ under the ticker JAZZ. The company is conducting clinical research on this investigational small molecule for the treatment of Acute Myeloid Leukemia.
ODSH is in Phase 1 clinical development. A Phase 1 trial, identified as NCT01843634, has been completed. This early-phase study evaluated the safety and efficacy of ODSH in patients with Acute Myeloid Leukemia. The drug remains investigational and has not received FDA approval.
ODSH has one completed clinical trial, NCT01843634, titled 'Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia'. This early Phase 1 study enrolled 10 participants in the United States and was not randomized or blinded.
ODSH is not known by any alternative names in the available information. It is a distinct investigational small molecule being developed by Jazz Pharmaceuticals for Acute Myeloid Leukemia. No other names for this drug have been reported.